(Q37937935)

25 August 2017

1 reference

title

Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer (English)

1 reference

25 August 2017

1 reference

1 reference

neoadjuvant chemotherapy

1 reference

1

Ignace Vergote

1 reference

25 August 2017

2

Frédéric Amant

1 reference

25 August 2017

Gunnar Kristensen

3

1 reference

25 August 2017

Tom Ehlen

series ordinal

4

1 reference

25 August 2017

Nick S Reed

series ordinal

5

1 reference

25 August 2017

Antonio Casado

series ordinal

6

1 reference

25 August 2017

publication date

1 September 2011

1 reference

European Journal of Cancer

25 August 2017

published in

1 reference

25 August 2017

volume

47 Suppl 3

1 reference

25 August 2017

page(s)

S88-92

1 reference

Advanced epithelial ovarian cancer: 1998 consensus statements

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970152-6

7 January 2021

The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970152-6

7 January 2021

Secondary surgical cytoreduction for advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970152-6

7 January 2021

Timing of debulking surgery in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970152-6

7 January 2021

Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970152-6

7 January 2021

Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970152-6

7 January 2021

Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970152-6

7 January 2021

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970152-6

7 January 2021

The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970152-6

7 January 2021

Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970152-6

7 January 2021

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970152-6

7 January 2021

What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970152-6

7 January 2021

Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970152-6

7 January 2021

Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography--a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970152-6

7 January 2021

Port-site metastases after open laparoscopy: a study in 173 patients with advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970152-6

7 January 2021

Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970152-6

7 January 2021

Diagnostic open laparoscopy in the management of advanced ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970152-6

7 January 2021

External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers: clues for a simplified score

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970152-6

7 January 2021

Trocar implantation metastasis after laparoscopy in patients with advanced ovarian cancer: can the risk be reduced?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970152-6

7 January 2021

Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenctomy have similar survival to Stage I/II patients and superior survival to other Stage III patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970152-6

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970152-6

7 January 2021

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970152-6

7 January 2021

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970152-6

7 January 2021

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970152-6

7 January 2021

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970152-6

7 January 2021

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970152-6

7 January 2021

Carcinoma of the Ovary

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970152-6

7 January 2021

Survival of Californian women with epithelial ovarian cancer, 1994-1996: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970152-6

7 January 2021

Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970152-6

7 January 2021

Specialized care and survival of ovarian cancer patients in The Netherlands: nationwide cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970152-6

7 January 2021

The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: Survey results from members of the Society of Gynecologic Oncologists

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970152-6

7 January 2021

10.1016/S0959-8049(11)70152-6

Identifiers

DOI

1 reference

25 August 2017

1 reference